{"preliminary_commentary":{"by_channel":{"youtube":9,"x_thread":9,"podcast":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03072238\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"IPATential 150","nct_id":"NCT03072238","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ipatential-150-nct03072238. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"IPATential150","arms":[{"description":"Participants received Placebo plus Abiraterone (along with Prednisone/Prednisolone), administered orally in 28-day cycles.","label":"Placebo + Abiraterone","type":"ACTIVE_COMPARATOR"},{"description":"Participants received Ipatasertib plus Abiraterone (along with Prednisone/Prednisolone), administered orally in 28-day cycles.","label":"Ipatasertib + Abiraterone","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-04-24","type":"ACTUAL"},"conditions":["Metastatic Prostate Cancer"],"enrollment":{"count":1101,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Ipatasertib","otherNames":[],"type":"DRUG"},{"name":"Abiraterone","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"},{"name":"Prednisone/Prednisolone","otherNames":[],"type":"DRUG"}],"last_update":"2025-06-06","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2020-03-16","type":"ACTUAL"},"primary_outcomes":[{"measure":"Investigator-assessed Radiographic Progression-free Survival (rPFS), Per Prostate Cancer Working Group 3 (PCWG3) Criteria in Phosphatase and Tensin Homolog (PTEN) Loss Population","timeFrame":"Up to approximately 32 months"},{"measure":"Investigator-assessed rPFS, Per PCWG3 Criteria in ITT Population","timeFrame":"Up to approximately 32 months"}],"references":[{"citation":"Matsubara N, de Bono J, Sweeney C, Chi KN, Olmos D, Sandhu S, Massard C, Garcia J, Chen G, Harris A, Schenkel F, Sane R, Hinton H, Bracarda S, Sternberg CN. Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer. Clin Genitourin Cancer. 2023 Apr;21(2):230-237.e1. doi: 10.1016/j.clgc.2023.01.001. Epub 2023 Jan 7.","pmid":"36697317","type":"DERIVED"},{"citation":"Kotani N, Wilkins JJ, Wade JR, Dang S, Sutaria DS, Yoshida K, Sundrani S, Ding H, Garcia J, Hinton H, Sane R, Chanu P. Characterization of exposure-response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study. Cancer Chemother Pharmacol. 2022 Dec;90(6):511-521. doi: 10.1007/s00280-022-04488-2. Epub 2022 Oct 28.","pmid":"36305957","type":"DERIVED"},{"citation":"Sweeney C, Bracarda S, Sternberg CN, Chi KN, Olmos D, Sandhu S, Massard C, Matsubara N, Alekseev B, Parnis F, Atduev V, Buchschacher GL Jr, Gafanov R, Corrales L, Borre M, Stroyakovskiy D, Alves GV, Bournakis E, Puente J, Harle-Yge ML, Gallo J, Chen G, Hanover J, Wongchenko MJ, Garcia J, de Bono JS. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2021 Jul 10;398(10295):131-142. doi: 10.1016/S0140-6736(21)00580-8.","pmid":"34246347","type":"DERIVED"}],"start_date":{"date":"2017-06-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT03072238"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ipatential-150-nct03072238"}